BioTuesdays

Tag - Mark Massaro

Markets

BTIG starts Sophia Genetics at buy; PT $6

BTIG initiated coverage of Sophia Genetics (NASDAQ:SOPH) with a “buy” rating and $6 price target. The stock price closed at $2.06 on Dec. 30. Sophia is a rapidly growing, global healthcare technology company that sells...

January 3, 2023
Akoya Logo
Markets

BTIG starts Akoya Biosciences at buy; PT $16

BTIG launched coverage of Akoya Biosciences (NASDAQ:AKYA) with a “buy” rating and $16 price target. The stock closed at $9.29 on June 21. Akoya is a rapidly growing life sciences technology company that offers a...

June 22, 2022
Talis-Logo
Markets

BTIG cuts Talis Biomedical to sell; PT $1

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “sell” from “neutral” with a price target of $1, citing a delay in the beta-phase rollout of the Talis One COVID-19 diagnostic, which was planned for the first quarter...

March 18, 2022
Mdx Health
Markets

BTIG starts MDx Health at buy; PT $15

BTIG launched coverage of MDx Health (NASDAQ:MDXH) with a “buy” rating and price target of $15. The stock closed at $9.04 on Nov. 26. MDx Health is a precision diagnostics company that offers a portfolio of...

November 29, 2021
Talis-Logo
Markets

BTIG cuts Talis Biomedical to neutral without PT

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “neutral” from “buy” and removed its price target after president, CEO, director and co-founder, Brian Coe, stepped down from the board and executive. The stock closed...

September 1, 2021
Talis-Logo
Markets

BTIG starts Talis Biomedical at buy; PT $18

BTIG initiated coverage of point-of-care diagnostics company, Talis Biomedical, (NASDAQ:TLIS) with a “buy” rating and $18 price target. The stock closed at $12.95 on March 8. “Consistent with our checks with KOLs … we...

March 9, 2021
Oncocyte
Markets

BTIG ups OncoCyte PT to $8 from $5

BTIG raised its price target for OncoCyte (NYSE American:OCX) to $8 from $5, citing a recent direct offering of $25-million with its two largest institutional shareholders, which gives the company “ammunition to execute...

January 26, 2021
T2 Biosystems Logo
Markets

Canaccord recommends buying T2 Biosystems on weakness

Canaccord Genuity reiterated its “buy” rating and $10 price target for T2 Biosystems (NASDAQ:TTOO), saying, “We would buy on weakness.” The stock was quoted at $3.71, down 58 cents, or 13%, in afternoon trading on March...

March 5, 2019